Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tumour markers: current status and future applications

K Aziz1

  • 1Center for Devices and Radiological Health, Food and Drug Administration, Rockville, MD 20857, USA.

Scandinavian Journal of Clinical and Laboratory Investigation. Supplementum
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Local Hemodynamic Conditions Associated with Focal Changes in the Intracranial Aneurysm Wall.

AJNR. American journal of neuroradiology·2019
Same author

Gold nanotriangles: scale up and X-ray radiosensitization effects in mice.

Nanoscale·2017
Same author

Assessment of endotracheal tube placement in newborn infants: a randomized controlled trial.

Journal of perinatology : official journal of the California Perinatal Association·2016
Same author

Assessment of endotracheal tube placement in newborn infants: a randomized controlled trial.

Journal of perinatology : official journal of the California Perinatal Association·2016
Same author

Wall Mechanical Properties and Hemodynamics of Unruptured Intracranial Aneurysms.

AJNR. American journal of neuroradiology·2015
Same author

Mask ventilation with two different face masks in the delivery room for preterm infants: a randomized controlled trial.

Journal of perinatology : official journal of the California Perinatal Association·2015

Tumour marker tests require well-established performance characteristics, including sensitivity and specificity, for screening, diagnosis, and monitoring. Evaluating these markers involves assessing their intended use, clinical utility, and prevalence within specific populations.

Area of Science:

  • Oncology
  • Medical Diagnostics
  • Biomarker Research

Background:

  • Tumour marker tests serve critical roles in cancer screening, diagnosis, and monitoring.
  • The performance of these tests relies heavily on sensitivity and specificity, which must align with their intended clinical application.

Purpose of the Study:

  • To outline the essential performance characteristics for tumour marker tests.
  • To emphasize the importance of aligning test claims with analytical and clinical sensitivity.
  • To detail the FDA's evaluation process for tumour marker tests, focusing on intended use and clinical utility.

Main Methods:

  • Review of tumour marker test evaluation criteria.
  • Analysis of performance parameters such as sensitivity, specificity, and prevalence.

Related Experiment Videos

  • Consideration of the impact of population prevalence on predictive value.

    • Main Results:

    • Tumour marker test value is determined by sensitivity and specificity, tailored to intended use.
    • FDA evaluation requires sponsors to substantiate all claims with robust scientific data.
    • Higher cancer prevalence in a population enhances the predictive value of a tumour marker test.

    Conclusions:

    • Accurate assessment of tumour marker tests necessitates a balance between analytical/clinical sensitivity and performance claims.
    • Clinical utility, particularly for screening, can be constrained by low cancer prevalence.
    • Rigorous scientific protocols and clinical studies are paramount for validating tumour marker tests.